Peptide World Congress 2026 Opens June 19-20 at Arizona Biltmore: Practitioner-Facing Annual Conference for Clinical Peptide Therapy on the Eve of FDA July PCAC Review
Peptide World Congress 2026 opens today (June 19-20, 2026) at Arizona Biltmore, LXR Hotels & Resorts in Phoenix, bringing together the clinical-peptide-prescriber community for two days of practitioner-focused sessions on therapeutic peptide protocols, dosing, indications, and case-based clinical reasoning. The agenda spans cellular aging, regenerative protocols, and clinical applications across orthopedic, metabolic, immune, and longevity indications. The conference falls roughly five weeks ahead of the July 23-24 FDA Pharmacy Compounding Advisory Committee meeting, which will determine whether BPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin, and the other Category-2-reclassified peptides advance toward 503A compounding-list eligibility. The community-conference format reflects how rapidly clinical peptide prescribing has moved from off-label specialty practice to a formal CME-adjacent ecosystem.